Oramed Pharmaceuticals announced randomization of patients in its first Phase 3 study of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D) is under way.
Oramed Pharmaceuticals has screened the first patients in its global Phase 3 trials of its oral insulin capsule ORMD-0801 for the treatment of type 2 diabetes (T2D).
Oramed Pharmaceuticals has screened the first patients in a global trial of its oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH).
Oramed Pharmaceuticals announced the FDA provided positive feedback during the company's End of Phase 2 (EOP2) meeting for Oramed's oral insulin (ORMD-0801).
Oramed Pharmaceuticals announced positive topline data from the second and final cohort of its Phase 2b trial evaluating the efficacy and safety of its lead oral insulin candidate ...